Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681020 | 1.00 | TACR1 (0.35) | TACR1PTGDR2CYP3A4KCNH2DGAT1 | |
| SCHEMBL679151 | 0.95 | FFAR4 (0.35) | TACR1PTGDR2CYP3A4KCNH2DGAT1 | |
| SCHEMBL679152 | 0.95 | FFAR4 (0.35) | TACR1PTGDR2CYP3A4KCNH2DGAT1 | |
| SCHEMBL681037 | 0.92 | CETP (0.34) | PTGDR2KCNH2LTC4SCETP | |
| SCHEMBL681036 | 0.92 | CETP (0.34) | PTGDR2KCNH2LTC4SCETP | |
| SCHEMBL680412 | 0.88 | CETP (0.33) | TACR1PTGDR2CYP3A4KCNH2DGAT1 | |
| SCHEMBL680413 | 0.88 | CETP (0.33) | TACR1PTGDR2CYP3A4KCNH2DGAT1 | |
| SCHEMBL680321 | 0.87 | KDM4E (0.36) | PTGDR2LTC4SCETP | |
| SCHEMBL680322 | 0.87 | KDM4E (0.36) | PTGDR2LTC4SCETP | |
| SCHEMBL680455 | 0.86 | TACR1 (0.39) | TACR1CYP3A4KCNH2DGAT1LTC4S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841478-B2 | Method for preparing trans-{4-[(alkylamino) methyl]- cyclohexyl}acetic acid ester | KOWA COMPANY, LTD. (JP) | 2014-09-23 | — | — | US | disclosed |
| EP-2383253-B1 | METHOD FOR MANUFACTURING TRANS-{4-[(ALKYL AMINO) METHYL]CYCLOHEXYL} ACETIC ESTER | KOWA CO (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | KOWA COMPANY, LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2383253-A1 | METHOD FOR MANUFACTURING TRANS-{4-Ý(ALKYL AMINO) METHYL¨CYCLOHEXYL} ACETIC ESTER | Kowa Company, Ltd. (JP) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288328-A1 | METHOD FOR PREPARING TRANS-ACETIC ACID ESTER | ACSL6, ACSL3, ACSL1 | TACR1 1559/4885PTGDR2 2631/4885CYP3A4 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.